Compare Olympus Corp. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with a 6.47% CAGR growth in Net Sales over the last 5 years
2
Poor long term growth as Net Sales has grown by an annual rate of 6.47% over the last 5 years
3
Flat results in Jun 26
4
With ROE of 11.32%, it has a expensive valuation with a 2.40 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 1,923,602 Million (Large Cap)
21.00
NA
0.00%
0.08
11.09%
2.37
Revenue and Profits:
Net Sales:
240,400 Million
(Quarterly Results - Jun 2026)
Net Profit:
19,102 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
20.13%
0%
20.13%
6 Months
43.06%
0%
43.06%
1 Year
8.38%
0%
8.38%
2 Years
-22.21%
0%
-22.21%
3 Years
-1.84%
0%
-1.84%
4 Years
-33.19%
0%
-33.19%
5 Years
-16.27%
0%
-16.27%
Olympus Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.47%
EBIT Growth (5y)
13.43%
EBIT to Interest (avg)
21.06
Debt to EBITDA (avg)
0.30
Net Debt to Equity (avg)
-0.01
Sales to Capital Employed (avg)
0.96
Tax Ratio
26.43%
Dividend Payout Ratio
48.93%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
22.11%
ROE (avg)
17.09%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
2.40
EV to EBIT
12.32
EV to EBITDA
8.54
EV to Capital Employed
2.32
EV to Sales
1.92
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
18.87%
ROE (Latest)
11.32%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
240,400.00
206,512.00
16.41%
Operating Profit (PBDIT) excl Other Income
49,104.00
29,156.00
68.42%
Interest
2,822.00
1,156.00
144.12%
Exceptional Items
0.00
0.00
Consolidate Net Profit
19,102.00
8,991.00
112.46%
Operating Profit Margin (Excl OI)
132.30%
62.70%
6.96%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 16.41% vs -12.06% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 112.46% vs -39.19% in Jun 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
1,010,676.00
997,332.00
1.34%
Operating Profit (PBDIT) excl Other Income
214,226.00
252,494.00
-15.16%
Interest
9,284.00
4,821.00
92.57%
Exceptional Items
-41,808.00
-23,539.00
-77.61%
Consolidate Net Profit
68,172.00
117,800.00
-42.13%
Operating Profit Margin (Excl OI)
145.50%
186.50%
-4.10%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 1.34% vs 7.73% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is -42.13% vs 235.95% in Mar 2025
About Olympus Corp. 
Olympus Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






